On December 21, our chairman Shi Yuanyuan, chief scientist Wang Jianxun, head of Marketing Sun Rui and Head of R&D Zhao Lijun went to Hong Kong Institute of Biotechnology for exchange visit. Dr. Jiang Gina, President of Hong Kong Biotechnology Research Institute, Dr. C.K.Wong, Deputy General manager, Dr. Maggie Z.y.How, Deputy general manager, warmly received and held discussions and exchanges to explore the future direction of cooperation.

At the symposium, first of all, Shi Yuanyuan, chairman of our company, introduced in detail the development history of Shenzhen Cell Valley, the core team, the advantages of retrovirus vectors used to prepare CAR T cells, four services - virus products, cell products, auxiliary declaration, talent training, GMP level production and construction, clinical application progress, major technological breakthroughs and enterprise comprehensive strength. The team of the Hong Kong Biotechnology Institute introduced the construction of advanced therapy products and GMP of ATP(andvanced Therapy Products). Shi Yuan said that Shenzhen Cell Valley has a GMP laboratory of 5,000 square meters that meets international standards, a number of viral vectors and CAT-T cell product production lines, and a R & D production team that has mastered the first industrial retrovirus vector technology (PackRV-SS system) in China, and has always focused on optimizing the process flow and cutting-edge technological innovation. At the same time, we continue to strengthen cooperation with scientific research institutes, pharmaceutical companies, universities, etc., establish the linkage of upstream and downstream industry chains, and achieve resource complementarity. At present, significant progress has been made in scientific research, clinical and industrial production. Dr. Gina Jiang, President of Hong Kong Biotechnology Research Institute, highly appreciated our company's deep technical heritage, spirit of scientific research innovation and talent training strength, and expressed the hope to carry out in-depth cooperation with Shenzhen Cell Valley, using the advantages of retroviral vector in industrial production of low cost, high yield, and strong combination with Shenzhen Cell Valley. Actively docking the innovative ecological resources of Hong Kong's industries, universities and research institutes, and promoting exchanges and cooperation in the biomedical industry between the two places.

This exchange visit has laid a good foundation for cooperation between the two sides. Shenzhen Cell Valley and Hong Kong Biotechnology Institute will cooperate in building a retrovirus-vector-based cell preparation industry chain, building a talent training mechanism for the industry, and jointly applying for Guangdong-Hong Kong-Shenzhen-Hong Kong cooperation projects, so as to jointly make positive contributions to the development of biomedicine in the Guangdong-Hong Kong-Macao Greater Bay Area.